Department of biochemistry and nuclear toxicology (SBTN)
BP 17171
F-30207 Bagnols-sur-Cèze
France
Secretariat :
Francine ROUX
Tel. : +33 4 66 79 19 01
Fax : +33 4 66 79 19 05
Joelle ILLIANO
Tel. : +33 4 66 79 19 02
Manager :
Éric EZAN
Tel. : +33 4 66 79 19 04
Email : eric.ezan@cea.fr
Perturbed Systems Biochemistry Laboratory (LBSP)
• conducting research into the protein regulation mechanisms involved in early stress response, and studying what happens when they are perturbed and the potential long-term consequences,
• pioneering novel methods for studying protein perturbation, focusing on intracellular relocation, differential proteomics, and post-translational modifications.
• pioneering novel methods for studying protein perturbation, focusing on intracellular relocation, differential proteomics, and post-translational modifications.
Molecular recognition and interactions laboratory (LIRM)
• Imaging single biological macromolecules using AFM
• Characterizing the energy landscape of unbinding molecular complexes
• Molecular modeling of protein-ligand complexes
• Developping software for AFM and molecular modeling
• Characterizing the energy landscape of unbinding molecular complexes
• Molecular modeling of protein-ligand complexes
• Developping software for AFM and molecular modeling
Cell engineering and biotechnology laboratory (LICB)
• designing and characterizing monoclonal and polyclonal antibodies and their target antigens (whether natural or synthetic) for the department’s own research and for joint research projects,
• to maintain cell banks for the SBTN (Dept. of Post-Genomic Biology and Nuclear Toxicology),
• running and developing a technological platform dedicated to recombinant production in a range of cell models,
• to partners independent research bodies on studies aimed at characterizing proteins and peptides of interest for human healthcare.
• to maintain cell banks for the SBTN (Dept. of Post-Genomic Biology and Nuclear Toxicology),
• running and developing a technological platform dedicated to recombinant production in a range of cell models,
• to partners independent research bodies on studies aimed at characterizing proteins and peptides of interest for human healthcare.
Laboratory of target protein studies (LEPC)
• identifying and validating, both in vivo and in vitro, metal ion and xenobiotic target proteins,
• studying the specific interactions between the target proteins identified and their biological partners and substrates,
• developing novel, highly-complex protein analysis techniques,
• studying the specific interactions between the target proteins identified and their biological partners and substrates,
• developing novel, highly-complex protein analysis techniques,
Environmental toxins detection and characterization laboratory (LDCAE)
• putting forward and developing immunochemistry and genetics-based methods for screening and identifying biological toxic agents such as microalgae, bacteria and viruses, or their toxins,
• studying the conditions for making sure that detection and characterization reagents are made secure and sustainable (including the design of non-toxic, non-infectious alternatives, stability of recombinant proteins, preservation and storage strategies),
• studying the conditions for making sure that detection and characterization reagents are made secure and sustainable (including the design of non-toxic, non-infectious alternatives, stability of recombinant proteins, preservation and storage strategies),
Laboratory of transporter imaging and oncological radiotherapy (TIRO)
• studying the role of the sodium and apical iodide transporters in post-accident diseases,
• scouting for effective counter-measures against radioiodine contamination,
• studying the therapeutic potential of using the sodium/iodide transporter (NIS protein) in radioactive iodine therapy for non-thyroid cancers,
• scouting for effective counter-measures against radioiodine contamination,
• studying the therapeutic potential of using the sodium/iodide transporter (NIS protein) in radioactive iodine therapy for non-thyroid cancers,